Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebicapone in Healthy Volunteers
NCT02763800Phase 1Completed
- Sponsor
- BIAL
- Start
- Sep 2000
- Primary completion
- Jan 2001
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nebicapone in Parkinson's disease (PD) (4 arms), sponsored by BIAL. Primary endpoints: Safety and tolerability of multiple dose regimens at 9 days, Maximum observed plasma concentration - Day 1 and 7 more. Started Sep 2000; status: completed.
02
Drugs
nebicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02763800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763800.